VYGR · Voyager Therapeutics, Inc.

Summary

Voyager Therapeutics announced the resignation of Chief Medical Officer Toby Ferguson, M.D., Ph.D., effective February 20, 2026, to pursue a new opportunity, with no disagreement cited. President and CEO Alfred W. Sandrock, Jr., M.D., Ph.D. will assume key clinical development responsibilities on an interim basis following the resignation.

Key takeaways

• Chief Medical Officer Toby Ferguson, M.D., Ph.D. resigned effective February 20, 2026.
• The resignation was to pursue a new opportunity and not due to any disagreement with the company.
• President and CEO Alfred W. Sandrock, Jr., M.D., Ph.D. will assume key responsibilities, including strategic guidance for clinical development programs, on an interim basis.
• The interim arrangement begins following the effective date of Dr. Ferguson's resignation.